title: Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab.
authors.affiliation: Department of Neurology and Brain Tumour Centre, University Hospital and University of Zurich, Zurich, Switzerland.
authors.forename: Patrick
authors.initials: P
authors.lastname: Roth
authors.affiliation: Department of Neuroradiology, University Hospital Zurich, Switzerland.
authors.forename: Antonios
authors.initials: A
authors.lastname: Valavanis
authors.affiliation: Department of Neurology, University Hospital Zurich, Switzerland.
authors.forename: Michael
authors.initials: M
authors.lastname: Weller
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D018450:Disease Progression; D004359:Drug Therapy, Combination; D005909:Glioblastoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D007167:Immunotherapy; D008875:Middle Aged; D000077594:Nivolumab / Q000627:therapeutic use*; D011379:Prognosis; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors* / Q000276:immunology; D012074:Remission Induction
chemical_list: D000911:Antibodies, Monoclonal; D000074322:Antineoplastic Agents, Immunological; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab
keywords: PD-1
  pseudoprogression; glioblastoma; iRANO; nivolumab